"Dermatologic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
| Descriptor ID |
D003879
|
| MeSH Number(s) |
D27.505.954.444
|
| Concept/Terms |
Dermatologic Agents- Dermatologic Agents
- Dermatological Agents
- Agents, Dermatological
- Agents, Dermatologic
- Dermatologic Agent
- Agent, Dermatologic
- Agent, Dermatological
- Dermatological Agent
|
Below are MeSH descriptors whose meaning is more general than "Dermatologic Agents".
Below are MeSH descriptors whose meaning is more specific than "Dermatologic Agents".
This graph shows the total number of publications written about "Dermatologic Agents" by people in this website by year, and whether "Dermatologic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dermatologic Agents" by people in Profiles.
-
Intralesional secukinumab for localized, recalcitrant hidradenitis suppurativa: a case series of rapid symptom relief. J Dermatolog Treat. 2026 Dec; 37(1):2660529.
-
Biologics in congenital ichthyosis: are they effective? Br J Dermatol. 2025 01 24; 192(2):327-334.
-
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus. Dermatology. 2024; 240(5-6):897-909.
-
Evaluating the Readability of the iPledge Comprehension Assessment and its Impact on Isotretinoin Accessibility. Pediatr Dermatol. 2025 Mar-Apr; 42(2):413-414.
-
Assessment of increased public interest in the safety of benzoyl peroxide. Int J Dermatol. 2024 Aug; 63(8):e192-e193.
-
IL17A Blockade with Ixekizumab Suppresses MuvB Signaling in Clinical Psoriasis. J Invest Dermatol. 2023 09; 143(9):1689-1699.
-
Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1. Lancet Infect Dis. 2023 05; 23(5):525-526.
-
Montelukast as an effective adjuvant in the treatment of moderate acne vulgaris. Dermatol Ther. 2022 10; 35(10):e15770.
-
A Case of Myelofibrosis and Myelodysplasia Identified Following Exposure to Isotretinoin. J Pediatr Hematol Oncol. 2021 01; 43(1):e136-e137.
-
Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences. Dermatol Ther. 2021 01; 34(1):e14486.